Drugs / gp160
gp160
Trials 14 · a red edge is where a trial was stopped
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000782 ↗ |
| Known as | gp160 Vaccine | “Evaluation of previous patients who received doses of 40 or 80 mcg gp160 vaccine indicates that, although serum anti-gp160 antibody responses were detected, the level and...” NCT00000956 ↗1“gp160 Vaccine (Immuno-AG)” NCT00001056 ↗ |
| Known as | gp160 Vaccine (MicroGeneSys) | “gp160 Vaccine (MicroGeneSys)” NCT00000757 ↗ |
| Known as | HIV GP160 | “HIV GP160 0.1 mg x 1 mL plus BCG Organism 50 MG Mix” NCT07182838 ↗ |
| Known as | HIV-1 recombinant envelope glycoprotein gp160 | “160 mcg HIV-1 recombinant envelope glycoprotein gp160” NCT00000757 ↗ |
| Known as | Immuno-AG | “gp160 Vaccine (Immuno-AG)” NCT00001056 ↗ |
| Known as | Recombinant GP160 HIV-1 Antigen | “Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity” NCT00000977 ↗ |
| Known as | VaxSyn | “Group A (20 volunteers) will receive gp160 (VaxSyn) followed two months later by a repeat dose.” NCT00000630 ↗1“soluble recombinant gp160 vaccine (VaxSyn)” NCT00000631 ↗ |
| Modality | Vaccine | “two candidate HIV vaccines, HIVAC-1e and gp160” NCT00000630 ↗ |
| Route | Other | “intradermal gp160” NCT00000667 ↗ |